News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Alexza Pharmaceuticals, Inc. Appoints Andreas Rummelt to its Board of Directors
February 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Andreas Rummelt, Ph.D., has been appointed a Director of Alexion, effective immediately.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Artificial intelligence
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics
September 25, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
September 24, 2026
·
2 min read
·
Nick Paul Taylor
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward
September 24, 2026
·
2 min read
·
Gabrielle Masson
Funding
Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs
September 24, 2026
·
1 min read
·
Tristan Manalac
